# MANUFACTURE AND PRECLINICAL TESTING OF SITE BLOCKING OLIGONUCLEOTIDES (SBO)

> **NIH NIH N01** · ADVANCED BIOSCIENCE LABORATORIES, INC. · 2024 · $1,899,037

## Abstract

This document outlines the scope of work and details necessary to provide a proposal for transfer of the 
current procedures for producing and testing research supplies, manufacture, and qualification of 
master cell banks (MCB) and viral stocks (MVSS), analytical methods development and qualification, 
production of reference standard, process development and scale-up, cGMP manufacturing of 
vHCA8*, and drug substance and drug product stability testing. It is important to note that, due to the 
nature of the vector, sterile filtration of the drug product is not possible and all manufacturing steps – 
upstream, downstream, and formulation/fill of drug product – must be performed under aseptic 
processing conditions.

## Key facts

- **NIH application ID:** 11211981
- **Project number:** 75N95022D00023-0-759502400001-1
- **Recipient organization:** ADVANCED BIOSCIENCE LABORATORIES, INC.
- **Principal Investigator:** CARY RETTERER
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $1,899,037
- **Award type:** —
- **Project period:** 2024-02-09 → 2027-02-08

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11211981

## Citation

> US National Institutes of Health, RePORTER application 11211981, MANUFACTURE AND PRECLINICAL TESTING OF SITE BLOCKING OLIGONUCLEOTIDES (SBO) (75N95022D00023-0-759502400001-1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/11211981. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*